Biopharmaceutical company Maikocan's IPO on the Science and Technology Innovation Board has been inquired. The company has accumulated a total loss of 1.141 billion yuan over the past three years.

According to the AI Finance app, on June 10th, Chengdu Maikang Life Sciences Co., Ltd. (referred to as Maikang) applied for a change in the review status for listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange to "inquiry received". China International Capital Corporation is the sponsoring institution, with plans to raise 2.929 billion yuan.